Summary
Unable to evaluate alignment with the supplied FDA-approved prescribing information because no FDA label text/sections were provided in the prompt. Therefore, none of the claims can be verified as supported, partially supported, or contradicted.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx is a human interleukin-17A (IL-17A) inhibitor.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx blocks the action of IL-17A.
No FDA prescribing information text/sections were provided to verify this claim.
IL-17A plays a key role in the development of autoimmune diseases.
No FDA prescribing information text/sections were provided to verify this claim.
By inhibiting IL-17A, Cosentyx reduces the production of pro-inflammatory cytokines.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx reduces inflammation in the skin.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx reduces inflammation in the joints.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx reduces inflammation in the spine.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx leads to improved symptoms in patients with autoimmune disorders.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx leads to reduced disease activity.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx inhibits activation and proliferation of immune cells.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx inhibits activation and proliferation of T-cells.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx inhibits activation and proliferation of macrophages.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx restores immune balance.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx reduces production of pro-inflammatory cytokines.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx increases production of anti-inflammatory cytokines.
No FDA prescribing information text/sections were provided to verify this claim.
Long-term effects of Cosentyx on the immune system are less well understood.
No FDA prescribing information text/sections were provided to verify this claim.
Long-term use of Cosentyx may lead to immunosuppression.
No FDA prescribing information text/sections were provided to verify this claim.
Immunosuppression from long-term use of Cosentyx can increase the risk of infections.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx increases the risk of infections.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx increases the risk of serious infections.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx increases the risk of tuberculosis.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx increases the risk of opportunistic infections.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx may alter the gut microbiome.
No FDA prescribing information text/sections were provided to verify this claim.
Alterations to the gut microbiome from Cosentyx can have long-term consequences for immune function and overall health.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx is effective in reducing symptoms in patients with psoriasis.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx improves quality of life in patients with psoriasis.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx is effective in reducing symptoms in patients with rheumatoid arthritis.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx improves quality of life in patients with rheumatoid arthritis.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx is effective in reducing symptoms in patients with ankylosing spondylitis.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx improves quality of life in patients with ankylosing spondylitis.
No FDA prescribing information text/sections were provided to verify this claim.
The long-term effects of Cosentyx are still not fully understood.
No FDA prescribing information text/sections were provided to verify this claim.
Cosentyx may increase the risk of infections, including serious infections such as tuberculosis and opportunistic infections.
No FDA prescribing information text/sections were provided to verify this claim.
Contradictions
Important Omissions
FDA-approved prescribing information (drug label) text/sections for Cosentyx (e.g., Indications and Usage, Dosage and Administration, Contraindications, Boxed Warning, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Studies).
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
Because label text was not provided, the risk-related claims (e.g., infections, tuberculosis, opportunistic infections, immunosuppression) cannot be verified against the FDA-approved label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Evaluated
Primary Issue
No FDA label text/sections were provided, so support/contradiction cannot be assessed.
Suggested Improvement
Provide the relevant FDA prescribing information text/sections (with section numbers if available) for Cosentyx so each claim can be classified as supported, partially supported, contradicted, absent, or off-label but medically plausible.